This article is more than 5 years old. Information may no longer be current.

CIBA Vision and CooperVision settle patent lawsuit

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

CIBA Vision has announced that it has reached a final global patent litigation agreement with CooperVision that resolves all current lawsuits, enabling "both companies to move forward in bringing forth new and improved innovations to meet the needs of eye care professionals and consumers," according to a press release from CIBA Vision.

As part of the agreement, CIBA Vision will license its Nicolson patents of high-oxygen-transmissible contact lenses to CooperVision, including its O2Optix, Air Optix and Night & Day silicone hydrogel contact lenses. In exchange, CooperVision will pay a royalty on U.S. net sales of its Biofinity contact lenses until 2014 and on net sales outside the United States until 2016.

In 2004, CIBA Vision settled a patent litigation settlement with Bausch & Lomb that also involved Nicolson patents. The two companies agreed at the time to cross-license rights to their silicone hydrogel contact lens technologies. As part of that settlement, Bausch & Lomb agreed to pay CIBA Vision a royalty on net U.S. sales of its PureVision brand contact lenses until 2014 and on net sales outside the United States until 2016.